Form 4: ICU Medical Executive Daniel Woolson Reports Stock Transactions
SEC Form 4 Filing
Daniel Woolson, VP, GM-Infusion Capital at ICU Medical, reports acquisition and disposal of common stock and derivative securities, including restricted stock units and performance-based restricted stock units.
Summary
- Daniel Woolson, a VP, GM-Infusion Capital at ICU Medical Inc., filed a Form 4 detailing changes in beneficial ownership.
- The transactions include the acquisition and disposal of common stock related to the vesting of Restricted Stock Units (RSUs) and Performance-based Restricted Stock Units (PRSUs).
- On March 7, 2024, 966 Restricted Stock Units vested, and 5,792 Performance Shares vested at 200% of the original grant.
- On March 8, 2024, 2,020 Performance Shares vested.
- The transactions also involved the disposal of shares to cover tax obligations at a price of $105.39 on March 7, 2024, and $104.52 on March 8, 2024.
- Following these transactions, Woolson directly owns 14,771 shares of common stock and 6,459 Restricted Stock Units.
Sentiment
Score: 6
Explanation: The document primarily reflects routine transactions related to executive compensation. The vesting of PRSUs at 200% is a positive indicator of company performance, but overall, the sentiment is neutral.
Positives
- The vesting of PRSUs at 200% suggests strong performance relative to the set metrics.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Comparison to Industry Standards
- Executive compensation packages often include a mix of salary, stock options, and restricted stock units.
- Vesting schedules for RSUs and PRSUs are common, typically ranging from 3 to 5 years.
- The vesting of PRSUs at 200% suggests that the company exceeded its performance targets, which is a positive sign.
- Companies like Medtronic and Baxter International also use similar equity-based compensation plans for their executives.
Stakeholder Impact
- The vesting of equity awards aligns management's interests with those of shareholders.
- The disposal of shares to cover tax obligations has a minimal impact on the overall market.
Key Dates
| Date | Description |
|---|---|
| 03/08/2021 | Date of grant for some of the Performance Shares that vested on March 8, 2024. |
| 03/07/2022 | Date of grant for some of the Performance Shares that vested on March 7, 2024. |
| 03/07/2023 | Date from which one third of the Restricted Stock Units granted on March 7, 2024, vest annually. |
| 03/07/2024 | Date of transactions involving vesting of Restricted Stock Units and Performance Shares, and disposal of shares for tax obligations. |
| 03/08/2024 | Date of transactions involving vesting of Performance Shares, and disposal of shares for tax obligations. |
| 03/11/2024 | Date of signature on the Form 4 filing. |
| 03/07/2025 | Expiration date of restricted stock units that fully vest 3 years from the grant date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.